Skip to content

Study · Randomized controlled trial · n = 1,011 · 2019

15 results

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend.

Deal CL, Mitlak BH, Wang Y, Fitzpatrick LA, Miller PD

Bone reports2 Nov 2019Cited by 4 (Europe PMC)

PMID31799340 (opens in a new tab)PMCIDPMC6883300 (opens in a new tab)DOI10.1016/j.bonr.2019.100230 (opens in a new tab)PepBankPUB-31799340
Read at sourcePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, all-site BMD response above 3% was more frequent with abaloparatide/alendronate than placebo/alendronate.

    In plain wordsAt Month 43, bone density gains above 3% at all sites occurred more often after abaloparatide then alendronate than placebo then alendronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseAll-site BMD response above 3%
    Study

    n = 1,011

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Measurements

    All-site response
    60.7%
    abaloparatide/alendronate
    All-site response
    24%
    placebo/alendronate

    Source sentences

    Summary
    At the>3% threshold, 60.7% (307/506) vs 24.0% (121/505) of patients experienced BMD increases at all 3 sites in the abaloparatide/alendronate vs placebo/alendronate groups, respectively (p < 0.001).
    2 context sentences
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, all-site BMD response above zero was more frequent with abaloparatide/alendronate than placebo/alendronate at Month 43.

    In plain wordsIn patients in ACTIVE and ACTIVExtend, bone density rose at all three sites more often with abaloparatide then alendronate than placebo then alendronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseAll-site BMD response above zero
    Study

    n: not reported in source

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    At Month 43, a significantly greater proportion of those in the abaloparatide/alendronate group compared with the placebo/alendronate group responded with BMD changes from ACTIVE baseline of >0%, >3%, and >6% at all 3 anatomic sites (p < 0.001 for each comparison).
    2 context sentences
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, all-site BMD response above 6% was more frequent with abaloparatide/alendronate than placebo/alendronate at Month 43.

    In plain wordsIn patients in ACTIVE and ACTIVExtend, bone density gains above 6% at all sites were more frequent with abaloparatide then alendronate than placebo then alendronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseAll-site BMD response above 6%
    Study

    n: not reported in source

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    At Month 43, a significantly greater proportion of those in the abaloparatide/alendronate group compared with the placebo/alendronate group responded with BMD changes from ACTIVE baseline of >0%, >3%, and >6% at all 3 anatomic sites (p < 0.001 for each comparison).
    2 context sentences
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, lumbar spine BMD responses above zero were more frequent with abaloparatide/alendronate than placebo/alendronate at 43 months.

    In plain wordsIn patients in ACTIVE and ACTIVExtend, spine bone density rose more often with abaloparatide then alendronate than placebo then alendronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine BMD response above zero
    Study

    n: not reported in source

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    A significantly greater proportion of the abaloparatide/alendronate group experienced BMD increases of>0%, >3%, and >6% at each individual anatomic site compared with the placebo/alendronate group at 43 months (p < 0.001).
    3 context sentences
    Summary · context
    Responders were defined as those patients who had improvements in BMD at 3 anatomic sites-the lumbar spine, total hip, and femoral neck. Three response thresholds, >0%, >3%, and >6%, were evaluated.
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, lumbar spine BMD responses above 3% were more frequent with abaloparatide/alendronate than placebo/alendronate at 43 months.

    In plain wordsIn patients in ACTIVE and ACTIVExtend, spine responses above 3% were more frequent with abaloparatide then alendronate than placebo then alendronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine BMD response above 3%
    Study

    n: not reported in source

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    A significantly greater proportion of the abaloparatide/alendronate group experienced BMD increases of>0%, >3%, and >6% at each individual anatomic site compared with the placebo/alendronate group at 43 months (p < 0.001).
    3 context sentences
    Summary · context
    Responders were defined as those patients who had improvements in BMD at 3 anatomic sites-the lumbar spine, total hip, and femoral neck. Three response thresholds, >0%, >3%, and >6%, were evaluated.
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, lumbar spine BMD responses above 6% were more frequent with abaloparatide/alendronate than placebo/alendronate at 43 months.

    In plain wordsIn patients in ACTIVE and ACTIVExtend, spine responses above 6% were more frequent with abaloparatide then alendronate than placebo then alendronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine BMD response above 6%
    Study

    n: not reported in source

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    A significantly greater proportion of the abaloparatide/alendronate group experienced BMD increases of>0%, >3%, and >6% at each individual anatomic site compared with the placebo/alendronate group at 43 months (p < 0.001).
    3 context sentences
    Summary · context
    Responders were defined as those patients who had improvements in BMD at 3 anatomic sites-the lumbar spine, total hip, and femoral neck. Three response thresholds, >0%, >3%, and >6%, were evaluated.
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, total hip BMD responses above zero were more frequent with abaloparatide/alendronate than placebo/alendronate at 43 months.

    In plain wordsIn patients in ACTIVE and ACTIVExtend, hip bone density rose more often with abaloparatide then alendronate than placebo then alendronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip BMD response above zero
    Study

    n: not reported in source

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    A significantly greater proportion of the abaloparatide/alendronate group experienced BMD increases of>0%, >3%, and >6% at each individual anatomic site compared with the placebo/alendronate group at 43 months (p < 0.001).
    3 context sentences
    Summary · context
    Responders were defined as those patients who had improvements in BMD at 3 anatomic sites-the lumbar spine, total hip, and femoral neck. Three response thresholds, >0%, >3%, and >6%, were evaluated.
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, total hip BMD responses above 3% were more frequent with abaloparatide/alendronate than placebo/alendronate at 43 months.

    In plain wordsIn patients in ACTIVE and ACTIVExtend, hip responses above 3% were more frequent with abaloparatide then alendronate than placebo then alendronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip BMD response above 3%
    Study

    n: not reported in source

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    A significantly greater proportion of the abaloparatide/alendronate group experienced BMD increases of>0%, >3%, and >6% at each individual anatomic site compared with the placebo/alendronate group at 43 months (p < 0.001).
    3 context sentences
    Summary · context
    Responders were defined as those patients who had improvements in BMD at 3 anatomic sites-the lumbar spine, total hip, and femoral neck. Three response thresholds, >0%, >3%, and >6%, were evaluated.
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).
  9. 09HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, total hip BMD responses above 6% were more frequent with abaloparatide/alendronate than placebo/alendronate at 43 months.

    In plain wordsIn patients in ACTIVE and ACTIVExtend, hip responses above 6% were more frequent with abaloparatide then alendronate than placebo then alendronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip BMD response above 6%
    Study

    n: not reported in source

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    A significantly greater proportion of the abaloparatide/alendronate group experienced BMD increases of>0%, >3%, and >6% at each individual anatomic site compared with the placebo/alendronate group at 43 months (p < 0.001).
    3 context sentences
    Summary · context
    Responders were defined as those patients who had improvements in BMD at 3 anatomic sites-the lumbar spine, total hip, and femoral neck. Three response thresholds, >0%, >3%, and >6%, were evaluated.
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).
  10. 10HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, femoral neck BMD responses above zero were more frequent with abaloparatide/alendronate than placebo/alendronate at 43 months.

    In plain wordsIn patients in ACTIVE and ACTIVExtend, femoral neck bone density rose more often with abaloparatide then alendronate than placebo then alendronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck BMD response above zero
    Study

    n: not reported in source

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    A significantly greater proportion of the abaloparatide/alendronate group experienced BMD increases of>0%, >3%, and >6% at each individual anatomic site compared with the placebo/alendronate group at 43 months (p < 0.001).
    3 context sentences
    Summary · context
    Responders were defined as those patients who had improvements in BMD at 3 anatomic sites-the lumbar spine, total hip, and femoral neck. Three response thresholds, >0%, >3%, and >6%, were evaluated.
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).
  11. 11HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, femoral neck BMD responses above 3% were more frequent with abaloparatide/alendronate than placebo/alendronate at 43 months.

    In plain wordsIn patients in ACTIVE and ACTIVExtend, femoral neck responses above 3% were more frequent with abaloparatide then alendronate than placebo then alendronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck BMD response above 3%
    Study

    n: not reported in source

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    A significantly greater proportion of the abaloparatide/alendronate group experienced BMD increases of>0%, >3%, and >6% at each individual anatomic site compared with the placebo/alendronate group at 43 months (p < 0.001).
    3 context sentences
    Summary · context
    Responders were defined as those patients who had improvements in BMD at 3 anatomic sites-the lumbar spine, total hip, and femoral neck. Three response thresholds, >0%, >3%, and >6%, were evaluated.
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).
  12. 12HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, femoral neck BMD responses above 6% were more frequent with abaloparatide/alendronate than placebo/alendronate at 43 months.

    In plain wordsIn patients in ACTIVE and ACTIVExtend, femoral neck responses above 6% were more frequent with abaloparatide then alendronate than placebo then alendronate.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck BMD response above 6%
    Study

    n: not reported in source

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    A significantly greater proportion of the abaloparatide/alendronate group experienced BMD increases of>0%, >3%, and >6% at each individual anatomic site compared with the placebo/alendronate group at 43 months (p < 0.001).
    3 context sentences
    Summary · context
    Responders were defined as those patients who had improvements in BMD at 3 anatomic sites-the lumbar spine, total hip, and femoral neck. Three response thresholds, >0%, >3%, and >6%, were evaluated.
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).
  13. 13HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, spine BMD response above 3% was more frequent with abaloparatide/alendronate than placebo/alendronate at each extension visit.

    In plain wordsIn patients in ACTIVE and ACTIVExtend, spine responses above 3% were more frequent with abaloparatide then alendronate than placebo then alendronate at each visit.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar spine response above 3% at each visit
    Study

    n: not reported in source

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Additionally, at each visit in ACTIVExtend, there was a significantly greater proportion of patients in the abaloparatide/alendronate group above the 3% threshold at each anatomic site compared with the placebo/alendronate group.
    3 context sentences
    Summary · context
    Responders were defined as those patients who had improvements in BMD at 3 anatomic sites-the lumbar spine, total hip, and femoral neck.
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).
  14. 14HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, hip BMD response above 3% was more frequent with abaloparatide/alendronate than placebo/alendronate at each extension visit.

    In plain wordsIn patients in ACTIVE and ACTIVExtend, hip responses above 3% were more frequent with abaloparatide then alendronate than placebo then alendronate at each visit.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTotal hip response above 3% at each visit
    Study

    n: not reported in source

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Additionally, at each visit in ACTIVExtend, there was a significantly greater proportion of patients in the abaloparatide/alendronate group above the 3% threshold at each anatomic site compared with the placebo/alendronate group.
    3 context sentences
    Summary · context
    Responders were defined as those patients who had improvements in BMD at 3 anatomic sites-the lumbar spine, total hip, and femoral neck.
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).
  15. 15HumanRandomized controlled trialEfficacy outcome

    In patients in ACTIVE and ACTIVExtend, femoral neck BMD response above 3% was more frequent with abaloparatide/alendronate than placebo/alendronate at each extension visit.

    In plain wordsIn patients in ACTIVE and ACTIVExtend, femoral neck responses above 3% were more frequent with abaloparatide then alendronate than placebo then alendronate at each visit.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral neck response above 3% at each visit
    Study

    n: not reported in source

    Comparator
    Placebo followed by alendronate
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Additionally, at each visit in ACTIVExtend, there was a significantly greater proportion of patients in the abaloparatide/alendronate group above the 3% threshold at each anatomic site compared with the placebo/alendronate group.
    3 context sentences
    Summary · context
    Responders were defined as those patients who had improvements in BMD at 3 anatomic sites-the lumbar spine, total hip, and femoral neck.
    Summary · context
    Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placebo/alendronate across the ACTIVE and ACTIVExtend studies.
    Summary · context
    BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend (18 months of abaloparatide or placebo followed by about 1 month for re-consent, followed by 24 months of alendronate treatment for a total of 43 months).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.